Patents Assigned to KUNMING INSTITUTE OF BOTANY, CHINESE ACADEMY OF SCIENCES
-
Publication number: 20240409552Abstract: Guaianolide oligomers 1-4 are represented by structural formula (I), a preparation method thereof, and a pharmaceutical composition thereof and the use thereof. The preparation method includes: the preparation of guaianolide diene via epoxy isomerization from arglabin-DMA, and a Diels-Alder reaction between the diene and sesquiterpenoid or oligomeric sesquiterpenoid containing ?, ?-unsaturated ?-lactone fragments and subsequent deprotection of NMe2 to obtain the guaianolide oligomers. The guaianolide oligomers inhibited the growth of human hepatoma cell lines HepG2, Huh7 and SK-Hep-1, and can form a pharmaceutical composition with a pharmaceutically acceptable carrier or excipient to be used for preparing an antihepatoma drug.Type: ApplicationFiled: September 6, 2022Publication date: December 12, 2024Applicant: KUNMING INSTITUTE OF BOTANY, CHINESE ACADEMY OF SCIENCESInventors: Jijun CHEN, Tianze LI, Yunbao MA, Changan GENG, Xuemei ZHANG
-
Patent number: 11925146Abstract: The present disclosure provides a cultivation method of morels and belongs to the technical field of cultivation of edible fungi. After nutrient contents that can be metabolized and utilized by morel mycelia are scientifically matched, sterilization treatment of exogenous nutrients is eliminated, and the exogenous nutrients are directly compressed for forming. Formed exogenous nutrient blocks and spawn is sowed and covered with soil, so as to realize a potential difference between “rich” and “poor” nutrients in a physical space. When the spawn germinate to form a mycelium network, the mycelia will enter a nutrient-rich exogenous nutrient area, secrete various extracellular enzymes to decompose and utilize these exogenous nutrient blocks, and transport them to a nutrient-poor mycelium network for storage, so as to complete nutrient assimilation and absorption, and reserve energy for later sexual reproduction.Type: GrantFiled: March 25, 2022Date of Patent: March 12, 2024Assignee: Kunming Institute of Botany, Chinese Academy of SciencesInventors: Xiaofei Shi, Wei Liu, Yingli Cai, Fuqiang Yu
-
Patent number: 11607417Abstract: The present disclosure relates to a celastrol or a pharmaceutically acceptable salt thereof, and a use thereof in the manufacture of a medicament for preventing and/or treating a cholestatic liver disease or a liver fibrosis.Type: GrantFiled: March 9, 2018Date of Patent: March 21, 2023Assignees: ZHEJIANG CHONGLING TECHNOLOGY CO., LTD., KUNMING INSTITUTE OF BOTANY, THE CHINESE ACADEMY OF SCIENCESInventors: Fei Li, Qi Zhao
-
Publication number: 20230055502Abstract: The present disclosure provides a cultivation method of morels and belongs to the technical field of cultivation of edible fungi. After nutrient contents that can be metabolized and utilized by morel mycelia are scientifically matched, sterilization treatment of exogenous nutrients is eliminated, and the exogenous nutrients are directly compressed for forming. Formed exogenous nutrient blocks and spawn is sowed and covered with soil, so as to realize a potential difference between “rich” and “poor” nutrients in a physical space. When the spawn germinate to form a mycelium network, the mycelia will enter a nutrient-rich exogenous nutrient area, secrete various extracellular enzymes to decompose and utilize these exogenous nutrient blocks, and transport them to a nutrient-poor mycelium network for storage, so as to complete nutrient assimilation and absorption, and reserve energy for later sexual reproduction.Type: ApplicationFiled: March 25, 2022Publication date: February 23, 2023Applicant: Kunming Institute of Botany, Chinese Academy of SciencesInventors: Xiaofei SHI, Wei Liu, Yingli Cai, Fuqiang Yu
-
Publication number: 20210186986Abstract: The present disclosure relates to a celastrol or a pharmaceutically acceptable salt thereof, and a use thereof in the manufacture of a medicament for preventing and/or treating a cholestatic liver disease or a liver fibrosis.Type: ApplicationFiled: March 9, 2018Publication date: June 24, 2021Applicants: KUNMING INSTITUTE OF BOTANY,THE CHINESE ACADEMY OF SCIENCES, ZHEJIANG CHONGLING TECHNOLOGY CO., LTD.Inventors: Fei Li, Qi Zhao
-
Patent number: 10603345Abstract: The invention provides a pharmaceutical composition for treating a respiratory disease, wherein the pharmaceutical composition comprises one or more components selected from picrinine, vallesamine, scholaricine, and 19-epischolaricine. The pharmaceutical composition has a good protective effect on the respiratory system, and can be used in treatment of a relevant disease.Type: GrantFiled: November 10, 2016Date of Patent: March 31, 2020Assignees: Kunming Institute of Botany, The Chinese Academy of Sciences, Kunming Beiao Technology Company LimitedInventors: Xiaodong Luo, Yunli Zhao, Jianhua Shang, Yaping Liu, Yifen Wang
-
Publication number: 20180344792Abstract: The invention provides a pharmaceutical composition for treating a respiratory disease, wherein the pharmaceutical composition comprises one or more components selected from picrinine, vallesamine, scholaricine, and 19-epischolaricine. The pharmaceutical composition has a good protective effect on the respiratory system, and can be used in treatment of a relevant disease.Type: ApplicationFiled: November 10, 2016Publication date: December 6, 2018Applicants: Kunming Institute of Botany, The Chinese Academy of Sciences, Kunming Beiao Technology Company LimitedInventors: Xiaodong Luo, Yunli Zhao, Jianhua Shang, Yaping Liu, Yifen Wang
-
Patent number: 10112918Abstract: The invention relates to a derivative of 15-oxospiramilacton, particularly to a compound of Formula I or II, or an isomer, a solvate or a pharmaceutically acceptable salt thereof. The invention also relates to a pharmaceutical composition comprising the compound as pharmaceutically active ingredient, a method for preparing the same, and use thereof in manufacture of an anti-tumor agent. The derivative of 15-oxospiramilactone of the invention have an activity against multiple tumor cell lines, and the anti-tumor activity is positively correlated to an activity inhibiting the Wnt signaling pathway.Type: GrantFiled: April 21, 2014Date of Patent: October 30, 2018Assignees: Kunming Institute of Botany, The Chinese Academy of Sciences, The Key Laboratory of Chemistry for Natural Product of Guizhou Province and Chinese Academy of Science, Shanghai Institutes of Biological Sciences, CAS, Institute of Zoology, Chinese Academy of SciencesInventors: Xiaojiang Hao, Chen Yan, Haiyang Liu, Lin Li, Xiaoli He, Quan Chen
-
Patent number: 9682954Abstract: The present invention relates to the pharmaceutical field, in particular to a phenanthridine derivative as shown in general formula (1) a pharmaceutical composition comprising the derivative, its preparation method, and its uses in manufacture of a medicament for the prevention or treatment of a disease related to the activity of Wnt signaling pathway, hepatitis C and hepatitis B.Type: GrantFiled: February 28, 2014Date of Patent: June 20, 2017Assignees: Kunming Institute of Botany, The Chinese Academy of Sciences, Shanghai Institutes for Biological Sciences, CAS, Institute of Medicinal Biotechnology, Chinese Academy of Medical SciencesInventors: Xiaojiang Hao, Duozhi Chen, Lin Li, Zonggen Peng, Jiandong Jiang, Yingtong Di, Junlin Yin, Sheng Wang, Jieyun Cai
-
Patent number: 9328084Abstract: Nitrogen-containing biphenyl compounds as represented by formula (I), pharmaceutically acceptable salts or derivatives thereof, pharmaceutical compositions, and preparation methods therefore, and anti-HIV-1 use of the compound. Each substituent group in formula (I) is as defined in the description.Type: GrantFiled: October 13, 2011Date of Patent: May 3, 2016Assignees: Kunming Institute of Botany, The Chinese Academy of Sciences, Yunnan University, Kunming Institute of Zoology, The Chinese Academy of SciencesInventors: Jingping Liu, Handong Sun, Hongbin Zhang, Yongtang Zheng, Weilie Xiao, Jianxin Pu, Ruirui Wang, Liumeng Yang
-
Publication number: 20160060364Abstract: A low-molecular-weight fucosylated glycosaminoglycan (aTFG) containing 2,5-anhydrated talose, alditol, glycosylamine or N-substituted glycosylamine monosaccharide composition thereof, preparation method thereof, pharmaceutical compositions containing the aTFG, and use thereof for preventing and/or treating thrombotic diseases are provided. The aTFG has potent anticoagulant activity targeting at intrinsic coagulation factor Xase, and inhibiting thrombogenesis, and therefore can be used as drugs for preventing and/or treating cardiovascular and cerebrovascular diseases.Type: ApplicationFiled: December 20, 2013Publication date: March 3, 2016Applicant: KUNMING INSTITUTE OF BOTANY, CHINESE ACADEMY OF SCIENCESInventors: Jinhua ZHAO, Mingyi WU, Na GAO, Zi LI, Sensen LAI, Longyan ZHAO
-
Patent number: 9163035Abstract: The present invention relates to pharmaceutical technical field, to melonine bisindole compounds, pharmaceutical compositions thereof, and preparation methods thereof. Specifically, the present invention relates to melonine bisindole compounds of Formula I, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts thereof. The present invention further relates to method for preparing the melonine bisindole compounds of Formula I or pharmaceutically acceptable salts thereof, and the use of the melonine bisindole compounds of Formula I or pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment or prophylaxis of cancers.Type: GrantFiled: November 4, 2010Date of Patent: October 20, 2015Assignee: Kunming Institute of Botany, The Chinese Academy of SciencesInventors: Xiaodong Luo, Tao Feng, Yan Li, Yuanyuan Wang, Xianghai Cai, Yaping Liu
-
Patent number: 9139502Abstract: The invention relates to a use of an urushiol compound (code named GQ-5) in preparation of pharmaceutical compositions for inhibiting Smad3 phosphorylation. We verify that GQ-5 inhibited the interaction of Smad3 with TGF-? type I receptor (T?RI), inhibited subsequent phosphorylation of Smad3, reduced nuclear translocation of Smads complex, and suppressed the transcription of major fibrotic genes such as ?-smooth muscle actin (?-SMA), collagen I and fibronectin. Therefore, GQ-5 could be a potent and selective inhibitor of TGF-?1-induced Smad3 phosphorylation, and be used to prepare pharmaceutical compositions for inhibiting Smad3 phosphorylation.Type: GrantFiled: November 3, 2014Date of Patent: September 22, 2015Assignees: SOUTHERN HOSPITAL, SOUTHERN MEDICAL UNIVERSITY, KUNMING INSTITUTE OF BOTANY, CHINESE ACADEMY OF SCIENCESInventors: Fan Fan Hou, Yongxian Cheng, Jing Nie, Jun Al, Jiangbo He
-
Publication number: 20150175511Abstract: The invention relates to a use of an urushiol compound (code named GQ-5) in preparation of pharmaceutical compositions for inhibiting Smad3 phosphorylation. We verify that GQ-5 inhibited the interaction of Smad3 with TGF-? type I receptor (T?RI), inhibited subsequent phosphorylation of Smad3, reduced nuclear translocation of Smads complex, and suppressed the transcription of major fibrotic genes such as ?-smooth muscle actin (?-SMA), collagen I and fibronectin. Therefore, GQ-5 could be a potent and selective inhibitor of TGF-?1-induced Smad3 phosphorylation, and be used to prepare pharmaceutical compositions for inhibiting Smad3 phosphorylation.Type: ApplicationFiled: November 3, 2014Publication date: June 25, 2015Applicants: SOUTHERN HOSPITAL, SOUTHERN MEDICAL UNIVERSITY, Kunming Institute of Botany, Chinese Academy of SciencesInventors: Fan Fan HOU, Yongxian CHENG, Jing NIE, Jun AI, Jiangbo HE
-
Patent number: 8859508Abstract: The present invention relates to the application of 5-methyl-1,3-benzenediol or its derivatives represented by Formula I; wherein the constituent variables are as defined herein or pharmaceutical compositions thereof containing them in the preparation of medicines or functional foods. The present studies indicate that 5-methyl-1,3-benzenediol or its derivatives represented by Formula I, wherein the constituent variables are as defined herein or pharmaceutical compositions thereof containing them show more significant antidepressant effects than fluoxetine or imipramine.Type: GrantFiled: July 25, 2008Date of Patent: October 14, 2014Assignees: Kunming Institute of Botany, Chinese Academy of Sciences, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming Jingbiao Biosciences R&D Co., Ltd.Inventors: Jijun Chen, Lin Xu, Jun Zhou, Jun Lu, Rongrong Mao, Meng Tian, Qixin Zhou, Xuemei Zhang, Yong Shen, Zhiyong Jiang, Aixue Zuo
-
Publication number: 20130331390Abstract: Nitrogen-containing biphenyl compounds as represented by formula (I), pharmaceutically acceptable salts or derivatives thereof, pharmaceutical compositions, and preparation methods therefore, and anti-HIV-1 use of the compound. Each substituent group in formula (I) is as defined in the description.Type: ApplicationFiled: October 13, 2011Publication date: December 12, 2013Applicants: Kunming Institute of Botany, The Chinese Academy of Sciences, Kunming Institute of Zoology, The Chinese Academy of Sciences, Yunnan UniversityInventors: Jingping Liu, Handong Sun, Hongbin Zhang, Yongtong Zheng, Weilie Xiao, Jianxin Pu, Ruirui Wang, Liumeng Yang
-
Publication number: 20120283284Abstract: The present invention relates to pharmaceutical technical field, to melonine bisindole compounds, pharmaceutical compositions thereof, and preparation methods thereof. Specifically, the present invention relates to melonine bisindole compounds of Formula I, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts thereof. The present invention further relates to method for preparing the melonine bisindole compounds of Formula I or pharmaceutically acceptable salts thereof, and the use of the melonine bisindole compounds of Formula I or pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment or prophylaxis of cancers.Type: ApplicationFiled: November 4, 2010Publication date: November 8, 2012Applicant: Kunming Institute of Botany, The Chinese Academy of SciencesInventors: Xiaodong Luo, Tao Feng, Yan Li, Yuanyuan Wang, Xianghai Cai, Yaping Liu
-
Publication number: 20100190730Abstract: The present invention relates to the application of 5-methyl-1,3-benzenediol or its derivatives represented by Formula I; wherein the constituent variables are as defined herein or pharmaceutical compositions thereof containing them in the preparation of medicines or functional foods. The present studies indicate that 5-methyl-1,3-benzenediol or its derivatives represented by Formula I, wherein the constituent variables are as defined herein or pharmaceutical compositions thereof containing them show more significant antidepressant effects than fluoxetine or imipramine.Type: ApplicationFiled: July 25, 2008Publication date: July 29, 2010Applicants: KUNMING INSTITUTE OF BOTANY, CHINESE ACADEMY OF SCIENCES, KUNMING INSTITUTE OF ZOOLOGY, CHINESE ACADEMY OF SCIENCES, KUNMING JINGBIAO BIOSCIENCES R&D CO., LTD.Inventors: Jijun Chen, Lin Xu, Jun Zhou, Jun Lu, Rongrong Mao, Meng Tian, Qixin Zhou, Xuemei Zhang, Yong Shen, Zhiyong Jiang, Aixue Zuo
-
Patent number: 7659308Abstract: The present invention relates to concentricolide and its derivatives, a method for the preparation of the compound and its derivatives, a pharmaceutical composition containing concentricolide and its derivatives, and use of the compound and its derivatives for the treatment and prevention of infection caused by human immunodeficiency virus (HIV).Type: GrantFiled: October 20, 2004Date of Patent: February 9, 2010Assignees: Kunming Institute of Botany, The Chinese Academy of Sciences, Kunming Institute of Zoology, The Chinese Academy of SciencesInventors: Jikai Liu, Yongtang Zheng, Xiangdong Qin, Liumeng Yang, Zejun Dong, Ruirui Wang, Jianwen Tan